培养阴性脓毒症可能是区别于培养阳性脓毒症的独立实体:一项前瞻性全国多中心队列研究
这项前瞻性全国多中心队列研究基于韩国脓毒症联盟登记,纳入20家医院21个ICU中符合Sepsis-3标准的脓毒症患者,最终分析3501例经急诊转入ICU的患者。培养阴性脓毒症占37%(1288例),病情较培养阳性组轻(SOFA评分更低、生命体征恶化更少),但血培养和經驗性抗生素给予更不及时、液体复苏依从性更低(96.9% vs 98.4%,p=0.038)、升压药使用更早(35.9% vs 31.1%,p=0.012)。总体院内病死率两组无显著差异(34.9% vs 31.6%,p=0.073),但在脓毒症休克患者中培养阴性组病死率更高(45.1% vs 37.6%,p=0.029),培养阴性独立预测不良预后(OR 1.462,95%CI 1.060-2.017,p=0.021)。作者认为,现行经验性抗生素适当性判定标准对培养阴性脓毒症可能不适用。
要点
- 脓毒症休克患者中,培养阴性脓毒症院内病死率高于培养阳性脓毒症(45.1% vs 37.6%,p=0.029)。
- 培养阴性脓毒症独立预测脓毒症休克患者不良预后(OR 1.462,95%CI 1.060-2.017,p=0.021)。
- 培养阴性脓毒症患者液体复苏依从性更低(96.9% vs 98.4%,p=0.038),升压药使用更早(35.9% vs 31.1%,p=0.012)。
- 培养阴性脓毒症的经验性抗生素适当性反而更高(96.8% vs 85.2%,p<0.001),作者认为现行适当性判定标准可能不适用于培养阴性脓毒症。
- 总体院内病死率两组无显著差异(34.9% vs 31.6%,p=0.073),但培养阴性组病情较轻(SOFA评分更低)、以肺部感染为主且呼吸衰竭发生率更高。
适用人群与场景
- 韩国脓毒症联盟登记中20家医院21个ICU的脓毒症患者,均为经急诊转入ICU、符合Sepsis-3标准者,研究期间为2019年9月至2021年12月。
- 共纳入11981例脓毒症患者,最终分析3501例(平均年龄72±13岁;1976例[56%]为男性)。
诊断标准与关键阈值
- 纳入标准:符合Sepsis-3标准的脓毒症患者。
- 培养阴性脓毒症定义为培养阴性,培养阳性脓毒症定义为培养阳性,依据原文分组。
红旗征与不能漏的情况
- 脓毒症休克合并培养阴性时病死率更高(45.1% vs 37.6%,p=0.029),且培养阴性独立预测不良预后(OR 1.462,95%CI 1.060-2.017,p=0.021)。
研究设计与关键结果
- 研究类型:前瞻性全国多中心队列研究,基于韩国脓毒症联盟登记,20家医院21个ICU,2019年9月至2021年12月,纳入符合Sepsis-3标准的脓毒症患者11981例,最终分析3501例经急诊转入ICU者。
- 分组:培养阳性脓毒症2213例(63%),培养阴性脓毒症1288例(37%);培养阴性组SOFA评分更低、生命体征恶化更少,以肺部感染为主且呼吸衰竭发生率更高。
- 过程指标:培养阴性组血培养和經驗性抗生素给予更不及时;液体复苏依从性培养阳性组98.4% vs 培养阴性组96.9%(p=0.038);升压药使用率培养阳性组31.1% vs 培养阴性组35.9%(p=0.012)。
- 主要结局:总体院内病死率培养阳性组31.6% vs 培养阴性组34.9%,无显著差异(p=0.073)。
- 亚组:脓毒症休克患者中,培养阴性组病死率45.1% vs 培养阳性组37.6%(p=0.029)。
- 经验性抗生素适当性:培养阴性脓毒症休克组96.8% vs 培养阳性脓毒症休克组85.2%(p<0.001)。
- 多因素分析:培养阴性独立预测脓毒症休克患者不良预后(OR 1.462,95%CI 1.060-2.017,p=0.021)。
证据类型、等级与局限
- 证据类型:前瞻性全国多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,现行经验性抗生素适当性判定标准可能不适用于培养阴性脓毒症。
- 在脓毒症休克患者中,培养阴性脓毒症病死率更高,需关注该类患者的预后。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The distinction between culture-positive sepsis and culture-negative sepsis regarding clinical characteristics and outcomes remains contentious. We aimed to elucidate these differences using large-scale nationwide data.
METHODS: This prospective cohort study analyzed data from the Korean Sepsis Alliance registry, comprising 21 intensive care units (ICUs) across 20 hospitals from September 2019 to December 2021. Patients meeting the Sepsis-3 criteria were included.
RESULTS: Among 11,981 sepsis patients, 3501 were analyzed, all of whom were referred to the ICU through the emergency department (mean age: 72 ± 13 years; 1976 [56%] males). Of these, 2213 (63%) were culture-positive sepsis and 1288 (37%) were culture-negative sepsis. Compared to the culture-positive sepsis group, the culture-negative sepsis group exhibited less severe illness, with lower Sequential Organ Failure Assessment scores and less deteriorated vital signs. While pulmonary-origin sepsis was common in both groups, culture-negative patients primarily presented with pulmonary infections and had a higher incidence of respiratory failure. In comparison to the culture-positive sepsis group, blood cultures and the administration of empirical antibiotics were performed less promptly in the culture-negative sepsis group. Patients with culture-negative sepsis also showed lower compliance with fluid resuscitation (98.4% vs. 96.9%, p = 0.038; culture-positive sepsis vs. culture-negative sepsis) and received vasopressors earlier (31.1% vs. 35.9%, p = 0.012). In-hospital mortality did not differ significantly between the two groups (31.6% vs. 34.9%, p = 0.073); however, in patients with septic shock, culture-negative sepsis had higher mortality rates (37.6% vs. 45.1%, p = 0.029). The apparent appropriateness of empirical antibiotics in the culture-negative septic shock was higher than that of the culture-positive septic shock (85.2% vs. 96.8%, p < 0.001). Culture-negativity independently predicted poor prognosis in septic shock patients (OR: 1.462, 95% CI [1.060-2.017], p = 0.021).
CONCLUSION: In patients with septic shock, culture-negativity was associated with increased mortality, despite the paradoxically higher appropriateness of empirical antibiotics than culture-positive patients. These contradictory findings suggest that the current criteria for determining the appropriateness of empirical antibiotic therapy may not be valid for culture-negative sepsis.
参考来源
- Chang Y, Oh JH, Oh DK, et al. Culture-negative sepsis may be a different entity from culture-positive sepsis: a prospective nationwide multicenter cohort study. Crit Care. 2024. PMID: 39587586. doi:10.1186/s13054-024-05151-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。